Prostate Cancer | Unmet Need | US/EU | 2016
The first-line mCRPC market is highly competitive due to the availability of several efficacious and safe hormonal agents that are well entrenched in this indication. Although these therapies have improved patient outcomes, significant unmet need still remains for novel therapies to build upon these outcomes and provide further benefits to first-line mCRPC patients. In this report, we examine the most important drivers of prescribing behavior and key unmet needs in this indication, and provide an in-depth analysis of the most significant commercial opportunities.
Related Market Assessment Reports
Report
Peripheral Arterial Disease – Current Treatment – Treatment Algorithms: Claims Data Analysis – Peripheral Artery Disease (US)
Peripheral artery disease (PAD) is a subtype of atherosclerotic cardiovascular disease affecting the arteries of the lower extremities and is associated with reduced walking capacity, claudication…
Report
Psoriatic Arthritis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Psoriatic Arthritis (US)
Treatment of psoriatic arthritis (PsA) typically begins with conventional disease-modifying antirheumatic drugs (DMARDs), such as methotrexate, and progresses to more potent biologics and/or…
Report
Biomarkers in Oncology – Access & Reimbursement – Access & Reimbursement – Biomarkers in Oncology – Biomarker-Driven Prescribing in NSCLC, Colorectal Cancer, Breast Cancer (US)
The increasing focus on biomarkers has reshaped the treatment paradigm in oncology, allowing physicians to tailor treatments to subpopulations of patients diagnosed with breast cancer, NSCLC and…
Report
Irritable Bowel Syndrome – Current Treatment – Treatment Algorithms: Claims Data Analysis – IBS-Constipation (including IBS without Diarrhea) (US)
Irritable bowel syndrome (IBS) is a chronic gastrointestinal disorder characterized by altered bowel motility, stool consistency, and frequency, and is classified into constipation-predominant,…
Report
Spinal Muscular Atrophy – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Spinal muscular atrophy (SMA) is a neuromuscular disease characterized by progressive muscle weakness and is a leading genetic cause of death in infants. SMA is divided into four clinical subtypes…
